- Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T
- KMID: 2504591
- Intest Res.
- 2020 Jul;18(3):343-344.
- doi: 10.5217/ir.2018.00078-c1
-
- CITED
-
- Close
- SHARE
-
- Close
- Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program
-
Ng IH, Cheung KK, Yau TT, Chow E, Ozaki R, Chan JC
- KMID: 2407117
- Endocrinol Metab.
- 2018 Mar;33(1):17-32.
- doi: 10.3803/EnM.2018.33.1.17
The rapid increase in diabetes prevalence globally has contributed to large increases in health care expenditure on diabetic complications, posing a major health burden to countries worldwide. Asians are commonly... -
- CITED
-
- Close
- SHARE
-
- Close
- Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
-
Okabayashi S, Kobayashi , Sujino T, Ozaki R, Umeda S, Toyonaga T, Saito E, Nakano M, Tablante M, Morinaga S, Hibi T
- KMID: 2396405
- Intest Res.
- 2017 Oct;15(4):535-539.
- doi: 10.5217/ir.2017.15.4.535
Extracolonic involvement of the gastrointestinal tract is extremely uncommon in ulcerative colitis (UC) and rarely found in the upper gastrointestinal tract or in postoperative cases since it typically responds to... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
-
Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T
- KMID: 2449963
- Intest Res.
- 2019 Apr;17(2):218-226.
- doi: 10.5217/ir.2018.00117
BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi , Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida , Saito E, Nakano M, Matsubara , Hisamatsu , Hibi T
- KMID: 2438447
- Intest Res.
- 2019 Jan;17(1):87-93.
- doi: 10.5217/ir.2018.00078
BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The... -
- CITED
-
- Close
- SHARE
-
- Close
